PROTAGENIC THERAPEUTICS INC (PTIX) Stock Price, Quote, News and Overview

Company Profile

Protagenic Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in New York City, New York and currently employs 1 full-time employees. Its lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide (TCAP), an endogenous brain signaling peptide that can dampen overactive stress responses. Its lead compound is a 41-amino-acid synthetic peptide, which focuses on treating various neuro-psychiatric conditions, including depression, anxiety, and post-traumatic stress disorder (PTSD). The company operates with a novel mechanism, mirroring the active part of the natural brain hormone TCAP, thereby reducing circulating cortisol levels. In addition, it has a portfolio of earlier stage neuropeptides targeting the TCAP pathway that are in preclinical evaluation. The initial dosage form is intended as a subcutaneous injection but is also amenable to other routes of administration including sublingually or intra-nasally.

Company Info

PROTAGENIC THERAPEUTICS INC

149 Fifth Avenue, Suite 500

New York City NEW YORK 10010 US

CEO: Garo H. Armen

Employees: 1

Company Website: https://protagenic.com/

Investor Relations: https://protagenic.com/investor/sec-filings/

Phone: 12129948200